Carevive Systems, Inc, Franklin, TN, USA.
Piedmont Research Strategies, Inc, Greensboro, NC, USA.
Value Health. 2022 Jun;25(6):931-936. doi: 10.1016/j.jval.2022.01.023. Epub 2022 Mar 23.
Remote patient monitoring became critical for patients receiving cancer treatment during the COVID-19 pandemic. We sought to test feasibility of an electronic patient symptom management program implemented during a pandemic. We collected and analyzed the real-world data to inform practice quality improvement and understand the patient experience.
Eligible patients had breast, lung, or ovarian cancers, multiple myeloma, or acute myeloid leukemia and 12 weeks of planned chemotherapy. Patients were notified that a symptom survey with common symptoms derived from the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events was available to complete using a smart phone, tablet, or computer. Patients recorded their symptoms and results were sent to the provider. Patients received care guidelines for mild/moderate severity symptoms and a phone call from the provider for severe reports.
A total of 282 patients generated > 119 088 data points. Patients completed 2860 of 3248 assigned surveys (88%), and 152 of 282 patients (54%) had symptom reports that generated an immediate notification to the provider. Longitudinal data were analyzed to determine whether previous reports predicted a notification alert and whether symptoms resolved after the alert was addressed.
An electronic patient symptom management program was implemented in the midst of the COVID-19 pandemic. Enrollment of 282 patients and a high survey completion (88%) demonstrated feasibility/acceptance. Patients reported symptoms at severe levels of 54% of the time and received self-management instructions and provider phone calls that resolved or decreased the severity of the symptom. A standard approach and validated instrument provide opportunities for improving and benchmarking outcomes.
在 COVID-19 大流行期间，远程患者监测对接受癌症治疗的患者至关重要。我们旨在测试在大流行期间实施电子患者症状管理计划的可行性。我们收集和分析真实数据，为实践质量改进提供信息，并了解患者体验。
符合条件的患者患有乳腺癌、肺癌或卵巢癌、多发性骨髓瘤或急性髓系白血病，且计划接受 12 周的化疗。患者会收到通知，可使用智能手机、平板电脑或计算机完成一项带有源自国家癌症研究所患者报告结局版常见不良事件术语标准的常见症状的症状调查。患者记录其症状，结果将发送给提供者。患者会收到轻度/中度严重症状的护理指南，如果报告的症状严重，将接到提供者的电话。
共有 282 名患者生成了超过 119088 个数据点。患者完成了 3248 项指定调查中的 2860 项（88%），282 名患者中有 152 名（54%）的症状报告会立即向提供者发出通知。对纵向数据进行了分析，以确定之前的报告是否预示着通知警报，以及在警报解决后症状是否缓解。
在 COVID-19 大流行期间实施了电子患者症状管理计划。282 名患者的入组和高调查完成率（88%）证明了该计划的可行性/可接受性。患者有 54%的时间报告严重程度的症状，并获得了自我管理指导和提供者电话，这些措施缓解或降低了症状的严重程度。标准方法和经过验证的工具为改善和基准测试结果提供了机会。
